About ImmuCell (NASDAQ:ICCC)
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio894
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$9.54 million
Price / Sales4.73
Cash Flow$0.27 per share
Price / Cash33.13
Book Value$4.07 per share
Price / Book2.20
Return on Equity0.28%
Return on Assets0.21%
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Corporation (NASDAQ:ICCC) issued its quarterly earnings data on Monday, November, 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. The biotechnology company earned $2.01 million during the quarter. ImmuCell had a return on equity of 0.28% and a net margin of 0.60%. View ImmuCell's Earnings History.
When will ImmuCell make its next earnings announcement?
Who are some of ImmuCell's key competitors?
Some companies that are related to ImmuCell include Ohr Pharmaceuticals (OHRP), Galectin Therapeutics (GALT), Senomyx (SNMX), Brainstorm Cell Therapeutics (BCLI), Abzena (ABZA), Navidea Biopharmaceuticals (NAVB), Novelion Therapeutics (NVLN), Vernalis (VER), OncoSec Medical (ONCS), ReNeuron Group (RENE), NovaBay Pharmaceuticals (NBY), Aptose Biosciences (APTO), CytRx (CYTR), OvaScience (OVAS), Tissue Regenix Group (TRX), Scancell (SCLP), Immutep (IMMP) and AEterna Zentaris (AEZS).
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- David Scott Tomsche, Independent Chairman of the Board (Age 59)
- Michael F. Brigham, President, Chief Executive Officer, Treasurer, Secretary, Director (Age 54)
- Elizabeth Luttrell Williams, Vice President - Manufacturing Operations
- Paul R. Wainman, Director (Age 50)
- David S. Cunningham, Independent Director (Age 49)
- Jonathan E. Rothschild, Independent Director (Age 61)
Who owns ImmuCell stock?
ImmuCell's stock is owned by a variety of of institutional and retail investors. Top institutional investors include
ROTHSCHILD JONATHAN E
(10.10%) and Essex Investment Management Co. LLC (0.53%). Company insiders that own ImmuCell stock include Brian L Pessin, David Cunningham, David Scott Tomsche and Joseph H Crabb. View Institutional Ownership Trends for ImmuCell.
Who bought ImmuCell stock? Who is buying ImmuCell stock?
ImmuCell's stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought ImmuCell stock in the last two years include Brian L Pessin, David Cunningham and David Scott Tomsche. View Insider Buying and Selling for ImmuCell.
How do I buy ImmuCell stock?
Shares of ImmuCell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ImmuCell stock can currently be purchased for approximately $8.94.
How big of a company is ImmuCell?
ImmuCell has a market capitalization of $45.16 million and generates $9.54 million in revenue each year. The biotechnology company earns $500,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. ImmuCell employs 45 workers across the globe.
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (ICCC)MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmuCell (NASDAQ:ICCC) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
ImmuCell (NASDAQ:ICCC) Earnings History and Estimates Chart
ImmuCell (NASDAQ ICCC) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018|| || || || || || || || |
|11/13/2017||Q3 2017||($0.07)||$2.01 million||View||N/A|
|8/14/2017||Q2 2017||($0.05)||$1.75 million||View||N/A|
|5/11/2017||Q1 2017||$0.12||$3.54 million||View||N/A|
|2/9/2017||Q416||$0.01||$2.70 million||$2.20 million||View||Listen|
|11/10/2016||Q316||$0.01||$1.61 million||$1.97 million||View||N/A|
|2/10/2016||Q315||$0.09||$2.21 million||$2.70 million||View||Listen|
|8/13/2015||Q215||$0.03||$1.54 million||$1.96 million||View||N/A|
|2/11/2015||Q414||$0.04||$1.56 million||$2.21 million||View||N/A|
|8/12/2014||Q214||($0.10)||$1.37 million||$1.54 million||View||N/A|
|2/13/2014||Q413||($0.05)||$1.42 million||$1.56 million||View||N/A|
|11/12/2013||Q313||$0.02||$1.08 million||$1.24 million||View||N/A|
|11/7/2012||Q312||($0.02)||$1.00 million||$1.08 million||View||N/A|
ImmuCell (NASDAQ:ICCC) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ImmuCell (NASDAQ:ICCC)
No dividend announcements for this company have been tracked by MarketBeat.com
ImmuCell (NASDAQ ICCC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.10%
Institutional Ownership Percentage: 13.22%
ImmuCell (NASDAQ ICCC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/27/2017||Brian L Pessin||Insider||Buy||30,000||$5.25||$157,500.00|| |
|3/14/2017||David Scott Tomsche||Director||Buy||2,000||$5.43||$10,860.00|| |
|11/7/2016||David Scott Tomsche||Director||Buy||4,000||$5.19||$20,760.00|| |
|7/8/2016||Joseph H Crabb||VP||Sell||1,935||$6.55||$12,674.25|| |
|7/7/2016||Joseph H Crabb||VP||Sell||2,691||$6.58||$17,706.78|| |
|7/5/2016||Joseph H Crabb||VP||Sell||5,374||$6.74||$36,220.76|| |
|3/21/2016||David Scott Tomsche||Director||Buy||955||$6.67||$6,369.85|| |
|1/29/2016||David Cunningham||Director||Buy||1,904||$5.25||$9,996.00|| |
|9/3/2015||Jonathan E. Rothschild||Director||Buy||3,000||$6.63||$19,890.00|| |
|9/1/2015||David Scott Tomsche||Director||Buy||1,000||$6.73||$6,730.00|| |
|8/31/2015||Jonathan E. Rothschild||Director||Buy||6,100||$7.37||$44,957.00|| |
|8/28/2015||David Scott Tomsche||Director||Buy||1,500||$7.27||$10,905.00|| |
|11/26/2014||Jonathan E Rothschild||Director||Buy||2,100||$4.82||$10,122.00|| |
|8/20/2014||Jonathan E Rothschild||Director||Buy||3,000||$4.55||$13,650.00|| |
|6/16/2014||Jonathan E Rothschild||Director||Buy||5,901||$4.57||$26,967.57|| |
|5/15/2014||David Cunningham||Director||Buy||1,500||$3.91||$5,865.00|| |
|8/23/2013||Jonathan E Rothschild||Director||Buy||1,500||$3.98||$5,970.00|| |
|8/16/2013||David Cunningham||Director||Buy||4,000||$3.68||$14,720.00|| |
ImmuCell (NASDAQ ICCC) News Headlines
|ImmuCell Corporation (ICCC) Releases Earnings Results|
www.americanbankingnews.com - November 14 at 9:56 AM
|Edited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMT|
finance.yahoo.com - November 14 at 5:47 AM
|ImmuCell Corp's (ICCC) CEO Michael Brigham on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 14 at 12:46 AM
|Immucell Corp (ICCC) Announces USDA Approval of New Product Claim to Prevent Rotavirus Infections|
www.streetinsider.com - November 13 at 7:46 PM
|ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections|
finance.yahoo.com - November 13 at 7:46 PM
|ImmuCell Announces Financial Results for Third Quarter of 2017|
finance.yahoo.com - November 13 at 7:46 PM
|ImmuCell Announces Completion of Construction of Nisin Production Facility|
finance.yahoo.com - November 8 at 10:04 AM
|ImmuCell Corporation (ICCC) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - November 6 at 12:17 PM
|ImmuCell to Announce Financial Results for Third Quarter of 2017|
finance.yahoo.com - November 3 at 8:51 AM
|ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017|
finance.yahoo.com - October 6 at 8:12 PM
|Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?|
finance.yahoo.com - October 5 at 10:47 AM
|ImmuCell Announces Expansion of Sales and Marketing Team|
finance.yahoo.com - September 14 at 6:18 AM
|ImmuCell Corp's (ICCC) CEO Michael Brigham on Q2 2017 Results - Earnings Call Transcript|
seekingalpha.com - August 15 at 11:55 PM
|Edited Transcript of ICCC earnings conference call or presentation 14-Aug-17 8:30pm GMT|
finance.yahoo.com - August 15 at 11:55 PM
|Investor Network: ImmuCell Corporation to Host Earnings Call|
finance.yahoo.com - August 14 at 10:03 PM
|ImmuCell Announces Financial Results for Second Quarter of 2017|
finance.yahoo.com - August 14 at 10:03 PM
|ImmuCell Co. (NASDAQ:ICCC) Announces Quarterly Earnings Results|
www.americanbankingnews.com - August 14 at 8:22 PM
|ImmuCell to Announce Financial Results for Second Quarter of 2017|
finance.yahoo.com - August 7 at 7:11 PM
|Insider Buying: ImmuCell Corporation (ICCC) Insider Buys 30,000 Shares of Stock|
www.americanbankingnews.com - July 28 at 7:35 PM
|ImmuCell Closes $1,000,000 Equity Investment|
finance.yahoo.com - July 27 at 10:14 PM
|ImmuCell Unveils New Website|
finance.yahoo.com - July 17 at 3:42 PM
|ImmuCell Clarifies Number of Authorized Common Shares|
finance.yahoo.com - July 14 at 3:18 AM
|IMMUCELL CORP /DE/ Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 30 at 6:12 PM
|IMMUCELL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Entry into a Material Definitive Ag|
biz.yahoo.com - March 8 at 6:36 PM
|IMMUCELL CORP /DE/ Files SEC form 8-K, Other Events|
biz.yahoo.com - March 2 at 6:11 PM
|ImmuCell Corporation (ICCC)|
seekingalpha.com - February 11 at 5:53 PM
|IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition|
biz.yahoo.com - February 10 at 6:34 PM
|Q4 2016 ImmuCell Corp Earnings Release - After Market Close|
biz.yahoo.com - February 9 at 6:43 PM
|ImmuCell's (ICCC) CEO Michael Brigham on Q3 2016 Results - Earnings Call Transcript|
seekingalpha.com - November 12 at 8:02 AM
|Immucell Corp (ICCC) Reports Q3 EPS of $0.01|
www.streetinsider.com - November 12 at 8:02 AM
|IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - October 21 at 5:39 PM
|Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%|
www.streetinsider.com - October 19 at 10:27 AM
|ImmuCell Announces Preliminary Third Quarter 2016 Financial Results|
www.streetinsider.com - October 18 at 10:37 AM
|ImmuCell to Raise $3.5 Million in Private Placement|
www.marketwatch.com - October 18 at 10:37 AM
|IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - October 18 at 10:37 AM
|ImmuCell Announces Second Quarter 2016 Financial Results|
www.finanznachrichten.de - August 13 at 8:31 AM
|ImmuCell's (ICCC) CEO Michael Brigham on Q2 2016 Results - Earnings Call Transcript|
seekingalpha.com - August 13 at 8:31 AM
|Immucell Corp (ICCC) Reports Q2 EPS of $0.00|
www.streetinsider.com - August 13 at 8:31 AM
|Q2 2016 ImmuCell Corp Earnings Release - After Market Close|
biz.yahoo.com - August 11 at 8:36 AM
|IMMUCELL CORP /DE/ Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders, Financial Statements an|
biz.yahoo.com - June 16 at 3:35 PM
ImmuCell (NASDAQ:ICCC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ImmuCell (NASDAQ:ICCC) Income Statement, Balance Sheet and Cash Flow Statement
ImmuCell (NASDAQ ICCC) Stock Chart for Wednesday, December, 13, 2017